Lexicon Pharmaceuticals
LXRX
86 hedge funds and large institutions have $221M invested in Lexicon Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 30 increasing their positions, 31 reducing their positions, and 17 closing their positions.
268% more call options, than puts
Call options by funds: $475K | Put options by funds: $129K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.93% less ownership
Funds ownership: 80.35% → 79.42% (-0.93%)
3% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 31
12% less capital invested
Capital invested by funds: $251M → $221M (-$30.3M)
15% less funds holding
Funds holding: 101 → 86 (-15)
71% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$729K |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$572K |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$477K |
| 4 |
Fisher Asset Management
Camas,
Washington
|
+$453K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$269K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$803K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$546K |
| 3 |
HF
HRT Financial
New York
|
-$506K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$447K |
| 5 |
Walleye Capital
New York
|
-$420K |
LXRX Hedge Fund Activity: Q2 2022 in Review
86 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2022, worth a combined $221M — down 12% from $251M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of LXRX and 5 opened new positions — a net loss of 12 holders — while 31 trimmed existing stakes and 30 added.
The largest buyer was Morgan Stanley, adding an estimated $729K. The largest seller was Nomura Holdings, cutting an estimated $803K.
- 86 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2022, down from 101 in Q1 2022.
- Funds reported $221M of Lexicon Pharmaceuticals stock for Q2 2022, down 12% quarter-over-quarter.
- 5 funds opened new Lexicon Pharmaceuticals positions in Q2 2022 and 17 closed out, a net change of -12 holders.
- The largest Lexicon Pharmaceuticals buyer in Q2 2022 was Morgan Stanley, an estimated $729K added.
- The largest Lexicon Pharmaceuticals seller in Q2 2022 was Nomura Holdings, an estimated $803K sold.
Based on aggregated 13F filings for Q2 2022.